References
- 1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. - 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200
- 2. Morrow DA, de Lemos JA. Benchmarks for the assessment of cardiovascular biomarkers. Circulation. 2007;115(8):949–952
- 3. Correale M, Monaco I, Brunetti ND, di Biase M, Metra M, Nodari S, et al. Redefining biomarkers in heart failure. 2018;23(2):237-253
- 4. Iaconetti C, Gareri C, Polimeni A, Indolfi C. Non-Coding RNAs: The “Dark Matter” of Cardiovascular Pathophysiology. Int J Mol Sci. 2013;14(10):19987-20018
- 5. Islas JF, Moreno-Cuevas JE. A MicroRNA Perspective on Cardiovascular Development and Diseases: An Update. Int J Mol Sci. 2018;19(7):2075-2090
- 6. Tian J, An X, Niu L. Role of microRNAs in cardiac development and disease. Exp Ther Med. 2017;13(1):3-8
- 7. Sárközy M, Kahán Zs, and Csont T. A myriad of roles of miR-25 in health and disease. Oncotarget. 2018;9(30):21580-21612
- 8. Wojciechowska A, Braniewska A, Kozar-Kamińska K. MicroRNA in cardiovascular biology and disease. Adv Clin Exp Med. 2017;26(5):865–874
- 9. Wang J, Liew OW, Chen Y-T. Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis. Int J Mol Sci. 2016;17(5):749-770
- 10. de Gonzalo-Calvo D, Iglesias-Gutiérrez E, Llorente-Cortés V. Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs. Rev Esp Cardiol (Engl Ed). 2017;70(9):763-769
- 11. Schulte C, Karakas M, Zeller T. microRNAs in cardiovascular disease – clinical application. Clin Chem Lab Med. 2017;55(5):687–704
- 12. Yan H, Ma F, Li Y, Zhangv Y, Wang C, Qiu D. miRNAs as biomarkers for diagnosis of heart failure. Medicine. 2017;96(22):22-32
- 13. Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J of Heart Fail. 2013;15(11):1277–1288
- 14. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, Kok WE, Pinto YM. MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res. 2010;106(6):1035-1039
- 15. Schmitter D, Voors AA, van der Harst P. HFpEF vs. HFrEF: can microRNAs advance the diagnosis? Eur J of Heart Fail. 2015;17(4):351–354
- 16. Nair N, Gupta S, Collier IX, Gongora E, Vijayaraghavan K. Can microRNAs emerge as biomarkers in distinguishing HFpEF versus HFrEF? Int. J. of Cardiology 2014;175(3):395–399
- 17. Oliveira-Carvalho V, Carvalho VO, Silva MM, Guimarães GV, Bocchi EA. MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq Bras Cardiol. 2012;98(4):362-369
- 18. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438(7068):685-689.
- 19. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980-984
- 20. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124(14):1537-1547